Share This Author
In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector
The ability of HIV-based viral vectors to deliver genes in vivo into nondividing cells could increase the applicability of retroviral vectors in human gene therapy.
A Third-Generation Lentivirus Vector with a Conditional Packaging System
It is demonstrated that the requirement for the tat gene can be offset by placing constitutive promoters upstream of the vector transcript, and the improved design presented here should facilitate testing of lentivirus vectors.
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
An HIV vector system in which the virulence genes env, vif, vpr, vpu, and nef have been deleted is described, and this multiply attenuated vector conserved the ability to transduce growth-arrested cells and monocyte-derived macrophages in culture, and could efficiently deliver genes in vivo into adult neurons.
Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery
The inactivation design achieved in this work improves significantly the biosafety of HIV-derived vectors, as it reduces the likelihood that replication-competent retroviruses will originate in the vector producer and target cells, and hampers recombination with wild-type HIV in an infected host.
Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.
Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector.
- L. Naldini, U. Blömer, F. Gage, D. Trono, I. Verma
- BiologyProceedings of the National Academy of Sciences…
- 15 October 1996
Development of clinically acceptable derivatives of the lentiviral vector may enable the sustained delivery of significant amounts of a therapeutic gene product in a wide variety of somatic tissues.
Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
Further vector refinement and/or development is required before gene therapy will become standard care for any individual disorder, and some clinical successes are over the horizon.
Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer.
It is reported that TIE2 expression in human blood identifies a subset of monocytes distinct from classical inflammatory monocytes and comprised within the less abundant "resident" population of blood monocytes, suggesting a potentially critical role of TEMs in human cancer progression.
Targeted Genome Editing in Human Repopulating Hematopoietic Stem Cells
Gene-edited HSCs sustained normal haematopoiesis and gave rise to functional lymphoid cells that possess a selective growth advantage over those carrying disruptive IL2RG mutations, which opens up new avenues for treating SCID-X1 and other diseases.